Intai Technology (4163) reported revenue of NT$253.7 million for Oct 2026, +49.0% year on year and +6.5% from the previous month. Revenue for Jan–Oct 2026 was NT$2.34 billion (+16.9% year on year).
Year-on-year revenue growth: 7 months in a row. →
In Oct 2026, it ranked No. 37 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$253.7 million | +49.0% | +6.5% |
| Sep 2026 | NT$238.3 million | +18.0% | -4.3% |
| Aug 2026 | NT$248.9 million | +18.4% | -14.2% |
| Jul 2026 | NT$290.2 million | +49.9% | +29.8% |
| Jun 2026 | NT$223.5 million | +7.7% | +1.3% |
| May 2026 | NT$220.6 million | +8.1% | -7.1% |
| Apr 2026 | NT$237.5 million | +20.3% | +8.6% |
| Mar 2026 | NT$218.7 million | -12.7% | +45.2% |
| Feb 2026 | NT$150.6 million | -15.7% | -40.6% |
| Jan 2026 | NT$253.5 million | +38.6% | +23.1% |
| Dec 2025 | NT$205.8 million | +9.8% | +1.9% |
| Nov 2025 | NT$202 million | -5.8% | +18.7% |
| Oct 2025 | NT$170.2 million | -3.8% | -15.7% |
| Sep 2025 | NT$202 million | +2.0% | -4.0% |
| Aug 2025 | NT$210.3 million | +14.4% | +8.6% |
| Jul 2025 | NT$193.6 million | -6.5% | -6.7% |
| Jun 2025 | NT$207.6 million | +30.7% | +1.7% |
| May 2025 | NT$204.1 million | -11.6% | +3.4% |
| Apr 2025 | NT$197.4 million | -8.4% | -21.2% |
| Mar 2025 | NT$250.5 million | +34.0% | +40.1% |
| Feb 2025 | NT$178.8 million | -2.1% | -2.3% |
| Jan 2025 | NT$182.9 million | -21.7% | -2.5% |
| Dec 2024 | NT$187.5 million | +12.4% | -12.5% |
| Nov 2024 | NT$214.4 million | +10.2% | +21.2% |
| Oct 2024 | NT$176.9 million | -20.6% | -10.7% |
Jan–Oct 2026 cumulative: NT$2.34 billion (+16.9% YoY)
Other Biotech & Medical companies
Compare with peers: Intai Technology vs PEC / Intai Technology vs Lotus Pharm / Intai Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16